- Home
- SILO vs KPRX Comparison
SILO vs KPRX Comparison
Compare SILO & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILO
- KPRX
- Stock Information
- Founded
- SILO 2010
- KPRX 1998
- Country
- SILO United States
- KPRX United States
- Employees
- SILO N/A
- KPRX N/A
- Industry
- SILO Apparel
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SILO Consumer Discretionary
- KPRX Health Care
- Exchange
- SILO Nasdaq
- KPRX Nasdaq
- Market Cap
- SILO 8.0M
- KPRX 9.2M
- IPO Year
- SILO N/A
- KPRX N/A
- Fundamental
- Price
- SILO $0.50
- KPRX $2.35
- Analyst Decision
- SILO
- KPRX Strong Buy
- Analyst Count
- SILO 0
- KPRX 1
- Target Price
- SILO N/A
- KPRX $10.00
- AVG Volume (30 Days)
- SILO 792.4K
- KPRX 55.6K
- Earning Date
- SILO 11-12-2025
- KPRX 11-07-2025
- Dividend Yield
- SILO N/A
- KPRX N/A
- EPS Growth
- SILO N/A
- KPRX N/A
- EPS
- SILO N/A
- KPRX N/A
- Revenue
- SILO $72,102.00
- KPRX N/A
- Revenue This Year
- SILO $1.86
- KPRX N/A
- Revenue Next Year
- SILO N/A
- KPRX N/A
- P/E Ratio
- SILO N/A
- KPRX N/A
- Revenue Growth
- SILO N/A
- KPRX N/A
- 52 Week Low
- SILO $0.40
- KPRX $2.21
- 52 Week High
- SILO $3.37
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- SILO 35.63
- KPRX 40.64
- Support Level
- SILO $0.50
- KPRX $2.22
- Resistance Level
- SILO $0.59
- KPRX $2.65
- Average True Range (ATR)
- SILO 0.05
- KPRX 0.19
- MACD
- SILO -0.01
- KPRX -0.02
- Stochastic Oscillator
- SILO 46.56
- KPRX 25.00
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.